Key Takeaways:
- The science-first longevity biotech company NOVOS landed fresh investment from Unilever Ventures.
- NOVOS was a BeautyMatter 2025 FUTURE50 brand, with industry experts projecting full-year 2025 revenue of $10 to $20 million.
- In a double-blind, randomized controlled trial at the University of Surrey, NOVOS Core far exceeded the effects typically observed with other supplements.
Unilever Ventures has taken a minority stake in NOVOS, reflecting a shared belief in science-led approaches to longevity.
WHO: Launched in 2021 by Chris Mirabile, NOVOS stemmed from his experience of being diagnosed with, and ultimately healed from, a brain tumor at age 16, which shifted his approach towards health and wellness to a mindset that was much more focused on longevity and disease avoidance. After two years of R&D, its flagship product, NOVOS Core, a nutritional formula, was developed to target all 12 major hallmarks of aging simultaneously. It has demonstrated the ability to improve skin health from the inside out; it also slows the biological pace of aging by addressing processes like cellular senescence, oxidative stress, and inflammaging. The formula has undergone a series of studies, starting with mechanistic in vitro studies, followed by a double-blind, randomized, placebo-controlled clinical trial in healthy populations. The brand is DTC-first, shipping to 180+ countries, with selective retail placement at Erewhon, Mayo Clinic stores, and select Equinox and Four Seasons properties.
The London-based corporate venture capital arm of the British multinational consumer goods company Unilever was founded in 2002 to invest in beauty and wellness brands, commerce-enabling...
